tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jami Rubin, 43 are a BUY (55.84%), 22 are a HOLD (28.57%), 12 are a SELL (15.58%).
Analyst Jami Rubin, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 78.43% that have a potential upside of 40.02% achieved within 788 days. Previously, Jami Rubin worked at MORGAN STANLEY.
Jami Rubin’s has documented 152 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 01-Oct-2018.
Analyst best performing recommendations are on TEVA (TEVA PHARMA INDUSTRIES LTD ADR).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 12/15/2017. The price target of $20 was fulfilled within 26 days with a profit of $1.39 (7.47%) receiving and performance score of 2.87.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 10-Sep-2026
$315
$51.04 (19.34%)
$265
12 days ago
(10-Sep-2026)
4/5 (80%)
$60 (23.53%)
148
Buy Since 12-Sep-2025
$303
$39.04 (14.79%)
$298
1 months 2 days ago
(20-Aug-2026)
2/8 (25%)
$41.17 (15.72%)
35
Buy Since 08-Dec-2021
$300
$36.04 (13.65%)
$295
1 months 5 days ago
(17-Aug-2026)
9/11 (81.82%)
$49.67 (19.84%)
469
Buy Since 23-Jan-2023
$260
$-3.96 (-1.50%)
$235
1 months 12 days ago
(10-Aug-2026)
9/9 (100%)
$12.03 (4.85%)
127
Buy Since 06-Feb-2020
$288
$24.04 (9.11%)
$261
1 months 18 days ago
(04-Aug-2026)
36/37 (97.3%)
$44.2 (18.13%)
434
What Year was the first public recommendation made by Jami Rubin?
